Guard Medical


Our Core Values

At Guard Medical, we create products that can help deliver a better quality of life for surgical patients. NPseal is a simple, easy-to-use dressing that delivers Negative Pressure Wound Therapy (NPWT) and may promote wound healing while lowering the barriers of high complexity and cost. Numerous peer reviewed studies have demonstrated the utility of NPWT in reducing the risk of surgical site complications. *

Smarter healing for everyone

We believe that all patients deserve smarter healing. By offering products that are easy-to-use and cost-effective, patients can receive well-known therapies that may promote healing.

Simplify the Complex

At Guard Medical, we know great solutions don’t need to be complicated. We obsess over creating simple and effective NPWT products that are easy for clinicians and patients to use.

Make Smarter Healing More Accessible

At Guard Medical, we understand that many patients who could benefit from negative pressure wound therapy aren’t offered it due to cost. We’re looking to dramatically change the cost of this therapy to allow more patients to benefit from smarter healing.

Elevate Patient Experience

At Guard Medical, we create products that can help deliver a better quality of life for surgical patients. We do this by focusing on solutions that may promote wound healing for happy patients and doctors.

Take a look
At our Instagram

1 month ago
1 month ago
1 month ago

Guard Medical In The Media

Meet Our Team

Machiel van der Leest

President & Founder
Machiel is a seasoned medical device professional and entrepreneur. He has developed and introduced over 10 class III devices in the interventional cardio- and neurovascular market. In his 20+ year career Machiel held executive positions as CTO, CSO and CEO. Prior to Guard Medical he was CEO of ART – bioresorbable stent. Machiel has raised funds and closed deals with an aggregated value of over $100 million. He holds a MSc degree from the Technical University Delft and is an inventor on 25+ patents.

Dr. Frederick Cornhill

CSO & Founder
Frederick has spent 40+ years working in MedTech start-ups both academic and commercial. He was the founding Chairman of Ohio State’s Biomedical Engineering (BME) Center, Cleveland Clinic’s Department of BME and Oxford University’s Institute of BME. Most recently, he was the Co-Director of the Minimally Invasive New Technology Program at NewYork-Presbyterian and Weill Cornell Medical Center. He received his doctorate from the University of Oxford in BME, has authored over 100 scientific articles and is an inventor on 40+ patents.

Laurence Lefebvre

COO & Founder
Laurence has 20+ years of experience in the development of medical technologies. Starting her career in medical imaging, she worked at Bain & Company focusing in healthcare before joining the Minimally Invasive New Technology Program. Most recently, she was a senior director at Lumendi leading the development of new devices in the GI field. Laurence holds a MSc in Bioengineering from Imperial College London and a MBA from Harvard Business School and is an inventor on 10+ patents.

Gene Paik

Vice President of Sales & Marketing

Gene has over 20 years of strategic leadership experience primarily in the healthcare arena. His career spans across a multitude of medical specialties and medical device organizations both large and small, including Medtronic. Gene has worked extensively in the sales and delivery of medical product and training solutions, partnering with globally recognized thought leaders and surgical societies. He holds MS degrees from Rosalind Franklin University/Chicago Medical School and a BA from University of California at Berkeley.

Sang Lee, MD

Sang is the Chief of Colon and Rectal Surgery at University of Southern California / Keck School of Medicine. Sang is one of the nation’s leading experts in laparoscopic colorectal and endoluminal surgeries. He has authored more than 75 original articles on colon and rectal surgery in peer-reviewed journals. Sang graduated from Johns Hopkins University with degree in biomedical engineering and obtained medical degree from New York University School of Medicine.

Meet Our Board of Directors

Philippe Boucheron

Philippe has over twenty years of life science investment experience. He is a Deputy Chief of Life Sciences Investment at Bpifrance and serves on boards of Ademtech, GamaMabs, Advicenne, NH TherAguix, Limflow and Corwave. He holds an MBA from INSEAD.

Philippe Dhamelincourt

Philippe is co-founder and Chairman of Matignon Investissement & Gestion. Philippe has been active in venture capital investment for nearly 40 years. After Arthur Andersen and SIMER, Philippe joined the Worms Bank in 1978 and became CEO of ACMER.

Phil Cooper

Phil has more than 30 years of experience in the medical device industry. Phil was President of Molnlycke Wound Care from 2007 to 2014 Phil is a non-executive director for listed LiDCO Group PLC, Alesi Surgical Limited and Soest Medical Group (NLD).

Thierry Sarda

Thierry has over 25 years of experience in the medical device industry in sales, marketing and general management. Thierry designed and lead major transformation programs in various healthcare sectors from hospital to homecare, in France and Europe.

Meet Our Partners

Interested in Making An Impact?

* Indications For Use per K240244

Strugala et al, Meta-Analysis of Comparative Trials Evaluating a Prophylactic Single-Use Negative Pressure Wound Therapy System for the Prevention of Surgical Site Complications, SURGICAL INFECTIONS Volume 18, Number 7, 2017

Hyldig, et al, Meta-analysis of negative-pressure wound therapy for closed surgical incisions, John Wiley &Sons on behalf of BJS Society, Ltd, 2016, 103; 477-486

Negative Pressure Vs. Dermabond

The patient was satisfied with both scars however he preferred the scar which was dressed with the NPseal® dressing.

With the purpose of evaluating the ease of use and the aesthetic result of the NPseal negative pressure wound therapy device, a direct comparison between Dermabond closure and NPseal negative pressure wound therapy was evaluated. Laparoscopic port site incisions were dressed with either Dermabond or the NPseal negative pressure wound therapy device and aesthetic and functional outcomes were evaluated.